Defence Therapeutics Inc. Announces New Unsecured Convertible Debentures Offering

Overview

Vancouver, British Columbia–(Newsfile Corp. – November 14, 2024) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, announces that it offers new unsecured convertible debentures (the “New Debentures”) for aggregate gross proceeds of up to CAD$1,570,000 (the “Offering”) in consideration for the settlement of the principal amounts owing to holders of the Previous Debentures (as defined below) (the “Outstanding Debt”). The New Debentures will be issued on a non-brokered private placement basis, bear interest at the rate of 8.0% per annum, be subject to a Conversion Event (as defined below), and mature on November 16, 2025 (the “Maturity Date”).

Expansion

Defence Therapeutics Inc. is a pioneering company in the field of biopharmaceuticals, focusing on developing cutting-edge radiopharmaceuticals, ADC products, and immune-oncology vaccines. The introduction of the New Debentures Offering represents a significant milestone for the company as it seeks to consolidate its financial position and address outstanding debts.

By issuing the New Debentures, Defence Therapeutics Inc. aims to secure additional funding to fuel its research and development efforts, accelerate the commercialization of its innovative products, and strengthen its market position in the biopharmaceutical industry. The Offering is a strategic move that demonstrates the company’s commitment to driving growth and advancing its mission of revolutionizing healthcare through groundbreaking therapies.

Impact on Individuals

As an individual, the introduction of the New Debentures Offering by Defence Therapeutics Inc. may not have a direct impact on you. However, indirectly, the success of the Offering and the company’s subsequent initiatives could lead to the development of new and improved healthcare solutions that benefit individuals worldwide.

Global Significance

The New Debentures Offering by Defence Therapeutics Inc. has the potential to have a significant impact on the biopharmaceutical industry and the global healthcare landscape. By raising funds through the Offering, the company can enhance its research and development capabilities, bring innovative therapies to market, and contribute to advancements in medical science that benefit populations around the world.

Conclusion

In conclusion, Defence Therapeutics Inc.’s announcement of the New Unsecured Convertible Debentures Offering marks a pivotal moment in the company’s journey towards driving innovation and transforming the healthcare industry. The Offering not only supports the company’s financial objectives but also paves the way for the development of groundbreaking therapies that have the potential to improve health outcomes and quality of life on a global scale.